Hiroyu Hatano

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:317-25. 2012
  2. ncbi A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response
    Hiroyu Hatano
    University of California, San Francisco, USA
    J Infect Dis 203:960-8. 2011
  3. ncbi Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, California, USA
    AIDS 24:2535-9. 2010
  4. ncbi Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy
    Hiroyu Hatano
    University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 54:389-93. 2010
  5. ncbi Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy
    Hiroyu Hatano
    San Francisco General Hospital, Building 80, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110, USA
    J Virol 83:329-35. 2009
  6. ncbi Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients
    Priscilla Y Hsue
    Division of Cardiology, Positive Health Program of the Department of Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 23:2021-7. 2009
  7. ncbi HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers
    Peter W Hunt
    Department of Medicine, University of California, San Francisco, California, USA
    Clin Infect Dis 52:681-7. 2011
  8. ncbi A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers
    Peter W Hunt
    Departments of Medicine and Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e15924. 2011
  9. ncbi HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control
    Brinda Emu
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    J Virol 82:5398-407. 2008
  10. ncbi Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen
    Hiroyu Hatano
    University of California San Francisco, San Francisco, CA, USA
    Clin Infect Dis 43:1329-36. 2006

Research Grants

  1. Virologic and host factors contributing to HIV control in elite controllers
    Hiroyu Hatano; Fiscal Year: 2007

Detail Information

Publications14

  1. ncbi A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:317-25. 2012
    ..To determine whether intensification with raltegravir improves endothelial function in antiretroviral-treated HIV-infected individuals...
  2. ncbi A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response
    Hiroyu Hatano
    University of California, San Francisco, USA
    J Infect Dis 203:960-8. 2011
    ..We conducted an intensification study to assess whether residual viral replication contributes to replenishment of the latent reservoir and whether mucosal HIV-specific T cell responses limit the reservoir size...
  3. ncbi Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, California, USA
    AIDS 24:2535-9. 2010
    ..HAART can effectively reduce plasma HIV RNA levels to below the level of detection in most HIV-infected patients. The degree to which residual low-level viremia persists during HAART remains unclear...
  4. ncbi Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy
    Hiroyu Hatano
    University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 54:389-93. 2010
    ..Although integrase inhibitors are highly effective in the management of drug-resistant HIV, some patients fail to achieve durable viral suppression. The long-term consequences of integrase inhibitor failure have not been well defined...
  5. ncbi Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy
    Hiroyu Hatano
    San Francisco General Hospital, Building 80, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110, USA
    J Virol 83:329-35. 2009
    ..This confirms the failure to eradicate the virus, even in these unique individuals who are able to reduce plasma viremia to very low levels without antiretroviral therapy...
  6. ncbi Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients
    Priscilla Y Hsue
    Division of Cardiology, Positive Health Program of the Department of Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 23:2021-7. 2009
    ..As endothelial dysfunction is central to the pathogenesis of atherosclerosis, we tested the hypothesis that current treatment with abacavir is associated with impaired endothelial function...
  7. ncbi HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers
    Peter W Hunt
    Department of Medicine, University of California, San Francisco, California, USA
    Clin Infect Dis 52:681-7. 2011
    ..Despite robust immune responses, these individuals never eradicate HIV infection. We hypothesized that HIV-specific CD4(+) T cells might serve as target cells for HIV, contributing to viral persistence in this setting...
  8. ncbi A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers
    Peter W Hunt
    Departments of Medicine and Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e15924. 2011
    ..These data support a model in which low frequencies of Tregs in HIV controllers may contribute to an effective adaptive immune response, but may also contribute to generalized immune activation, potentially contributing to CD4 depletion...
  9. ncbi HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control
    Brinda Emu
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    J Virol 82:5398-407. 2008
    ..Defining mechanisms for virus control in "non-T-cell controllers" might lead to insights into preventing HIV transmission or preventing virus replication...
  10. ncbi Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen
    Hiroyu Hatano
    University of California San Francisco, San Francisco, CA, USA
    Clin Infect Dis 43:1329-36. 2006
    ..Resistance mutations vary over time, which suggests that the results of any single resistance test may not be representative of all mutations selected by a given treatment regimen...
  11. ncbi Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes
    Peilin Li
    University of California, San Francisco UCSF, Department of Medicine, San Francisco, CA 94121, USA
    J Virol Methods 170:115-20. 2010
    ..765, p<0.0001). This approach to Taqman probe design should be explored further for use in diagnosis and monitoring of HIV in resource-limited settings, especially where several subtypes co-circulate...
  12. ncbi Drug resistant HIV
    Hiroyu Hatano
    BMJ 334:1124-5. 2007
  13. ncbi Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, and Division of AIDS, Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 45:494-500. 2007
    ..These results show that Delta70 enhances resistance to certain purine and pyrimidine analogues and contributes to multinucleoside resistance in the appropriate viral genetic background...
  14. ncbi Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women's Hospital, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Virol 80:7020-7. 2006
    ..These results help explain why T215Y but not T215F usually emerges as the first major TAM, as well as the clustering of L210W with TAM-1 mutations and T215F with TAM-2 mutations...

Research Grants2

  1. Virologic and host factors contributing to HIV control in elite controllers
    Hiroyu Hatano; Fiscal Year: 2007
    This is an application for a K23 award for Dr. Hiroyu Hatano, a fellow in adult infectious diseases at the University of California, San Francisco who is establishing herself as a young investigator in patient-oriented translational ..